医疗ETF 14:00事件流｜2026-08-14（3条）

[ { "event_id": "valneva-eu-20260814-lyme-vaccine-maa", "title": "EMA 受理辉瑞与 Valneva 莱姆病疫苗申请", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-08-14T05:00:00Z", "event_type": "drug_approval", "asset_keys": ["MEDICAL"], "direction_score": {"MEDICAL": 1}, "confidence": 97, "horizon": "weeks", "raw_facts": "辉瑞与 Valneva 宣布，欧洲药品管理局已受理 PF-07307405 的上市许可申请并将开始审评。PF-07307405 为六价 OspA 莱姆病疫苗候选，申请基于 III 期 VALOR 试验（NCT05477524）：9,437 名 5 岁及以上参与者按 1:1 随机入组，观察到超过 70%的保护效力；公司称疫苗耐受性良好，未发现安全性问题。该候选已完成两项关键 III 期试验，目前尚无获批的人用莱姆病疫苗。", "transmission_chain": "EMA 确认申请材料有效并启动审评→该候选从申报转入正式审评，申报完整性风险下降→创新疫苗管线与海外药企研发情绪获得边际支持；本次只是受理而非批准，MEDICAL 方向取+1。", "invalidation_conditions": "EMA 暂停或终止审评、要求重新申报、申请被撤回或最终被拒，后续正式披露修正 VALOR 试验超过 70%的保护效力，或审评中出现新的重大安全性信号。", "source_urls": [ "https://valneva.com/press-release/pfizer-and-valnevas-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency/", "[https://www.[globenewswire.com/news-release/2026/08/14/3345081/0/en/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency.html](https://www.globenewswire.com/news-release/2026/08/14/3345081/0/en/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency.html)](https://globenewswire.com/news-release/2026/08/14/3345081/0/en/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency.html](https://www.globenewswire.com/news-release/2026/08/14/3345081/0/en/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency.html))" ], "source_tier": "A" }, { "event_id": "dart-kr-20260814-samil-h1-results", "title": "Samil 上半年营收降 2.8%且亏损扩大", "event_time_utc": "2026-08-14T05:45:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-14T05:45:00Z", "event_type": "sales_data", "asset_keys": ["MEDICAL"], "direction_score": {"MEDICAL": -1}, "confidence": 98, "horizon": "weeks", "raw_facts": "韩国金融监督院 DART 于 2026 年 8 月 14 日 14:45 KST 受理 Samil Pharmaceutical（KOSPI 000520）的 2026 年半年度报告。合并营收为 103,149,352,947 韩元，上年同期 106,073,620,548 韩元，同比下降 2.8%；营业亏损 14,706,526,900 韩元，上年同期亏损 8,485,016,709 韩元，亏损扩大 73.3%；净亏损 18,523,981,224 韩元，上年同期亏损 15,578,612,900 韩元，亏损扩大 18.9%。制药业务占合并营收 97.3%，其他业务占 2.7%；公司称越南子公司的 33 亿韩元折旧费、16 亿韩元修缮费等合计 115 亿韩元销售及管理费用，是营业亏损的主要原因。", "transmission_chain": "上半年营收同比下降 2.8%，营业亏损和净亏损分别扩大 73.3%和 18.9%→制药主业收入与海外产能成本未能覆盖费用→韩国制药同业盈利预期承压，作为海外同业信号对 MEDICAL 构成间接负面影响，方向取-1。", "invalidation_conditions": "DART 后续更正本期或上年同期收入与亏损数据，越南子公司折旧和修缮等阶段性费用消退并使下半年营业利润转正，或公司上调全年收入和利润指引并由正式财报验证。", "source_urls": [ "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814001835", "https://dart.fss.or.kr/report/viewer.do?rcpNo=20260814001835&dcmNo=11531194&eleId=1&offset=0&length=0&dtd=6" ], "source_tier": "A" }, { "event_id": "dart-kr-20260814-jeil-h1-results", "title": "Jeil 上半年营收降 7.9%并由盈转亏", "event_time_utc": "2026-08-14T05:53:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-14T05:53:00Z", "event_type": "sales_data", "asset_keys": ["MEDICAL"], "direction_score": {"MEDICAL": -1}, "confidence": 98, "horizon": "weeks", "raw_facts": "韩国金融监督院 DART 于 2026 年 8 月 14 日 14:53 KST 受理 Jeil Pharmaceutical（KOSPI 002620）的 2026 年半年度报告。合并营收为 276,902,290,951 韩元，上年同期 300,652,120,178 韩元，同比下降 7.9%；营业亏损 6,626,613,727 韩元，上年同期营业利润 10,339,829,824 韩元，由盈转亏；净亏损 3,449,917,716 韩元，上年同期净利润 6,665,005,994 韩元，由盈转亏。第二季度单季营收 146,604,024,528 韩元，上年同期 137,628,245,268 韩元。", "transmission_chain": "上半年营收同比下降 7.9%，营业利润与净利润同时由盈转亏→韩国处方药同业的费用与经营杠杆承压→海外制药盈利信号转弱，对 MEDICAL 的风险偏好构成间接负面影响；第二季度营收同比回升限制负面幅度，方向取-1。", "invalidation_conditions": "DART 后续更正本期或上年同期收入与利润数据，下半年收入增长恢复并推动营业利润和净利润转正，或公司正式上调全年业绩指引并由后续财报验证。", "source_urls": [ "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814001908", "https://dart.fss.or.kr/report/viewer.do?rcpNo=20260814001908&dcmNo=11531428&eleId=1&offset=0&length=0&dtd=6" ], "source_tier": "A" } ]